John Shannon was appointed Chief Executive Officer in August 2024. He joined Xeris in 2017 as Chief Operating Officer and was promoted to President in 2020. Mr. Shannon has 35+ years of pharmaceutical and healthcare experience with a diverse background in sales, global and US marketing, operations and manufacturing, strategic planning, and business development.
Prior to Xeris, Mr. Shannon spent two years as Chief Executive Officer for Catheter Connections, Inc., a company focused on the development and commercialization of innovative vascular access products designed to protect patients from acquiring infections during intravenous infusion therapy. Catheter Connections, Inc. was acquired by Merit Medical in January 2016.
Before Catheter Connections, Mr. Shannon spent three years as Chief Commercial Officer for Durata Therapeutics, a biopharmaceutical company focused on the development and commercialization of differentiated therapeutic solutions to advance patient care in infectious disease and acute illnesses. Durata was acquired by Actavis (now Allergan) in November 2014. Mr. Shannon spent 10 years (2001–2011) at Baxter Healthcare, where he was General Manager, Global Hemophilia and Global Commercial Excellence; General Manager, US Biopharmaceuticals; Vice President, Marketing US Bioscience; and Vice President, Marketing US Renal. During his time at Baxter, he led the commercialization and drove the growth of two Baxter brands, ADVATE® and GAMMAGARD®, both of which now exceed revenues of $1 billion.
Prior to coming to Baxter, Mr. Shannon was Vice President, Marketing for Caremark. Before that, he was at Searle for 10 years; there, he held several positions, most notably Executive Director, Cardiovascular Global Commercialization, in which he was responsible for the commercial development and marketing of new cardiovascular products worldwide, and Senior Director of Cox-2 Global Commercialization, in which he led the worldwide launch and global marketing of Celebrex®. In addition, he spent 7 years at Bock Pharmacal Company, where he held various positions including Sales Representative, Sales Trainer, Sales Operations, Marketing, Strategic Planning, and Business Development.
Mr. Shannon holds a BS in Biology with an emphasis in Microbiology from Western Illinois University.
What is John Patrick Shannon, Jr.'s net worth?
The estimated net worth of John Patrick Shannon, Jr. is at least $6.94 million as of November 17th, 2023. Mr. Shannon, Jr. owns 1,408,575 shares of Xeris Biopharma stock worth more than $6,944,275 as of May 31st. This net worth estimate does not reflect any other assets that Mr. Shannon, Jr. may own. Learn More about John Patrick Shannon, Jr.'s net worth.
How do I contact John Patrick Shannon, Jr.?
Has John Patrick Shannon, Jr. been buying or selling shares of Xeris Biopharma?
John Patrick Shannon, Jr. has not been actively trading shares of Xeris Biopharma during the last quarter. Most recently, on Friday, November 17th, John Patrick Shannon, Jr. bought 30,769 shares of Xeris Biopharma stock. The stock was acquired at an average cost of $1.64 per share, with a total value of $50,461.16. Following the completion of the transaction, the insider now directly owns 1,408,575 shares of the company's stock, valued at $2,310,063. Learn More on John Patrick Shannon, Jr.'s trading history.
Who are Xeris Biopharma's active insiders?
Are insiders buying or selling shares of Xeris Biopharma?
In the last year, Xeris Biopharma insiders bought shares 1 times. They purchased a total of 4,285 shares worth more than $10,155.45. In the last year, insiders at the sold shares 1 times. They sold a total of 40,000 shares worth more than $217,200.00. The most recent insider tranaction occured on March, 20th when insider Beth Hecht sold 40,000 shares worth more than $217,200.00. Insiders at Xeris Biopharma own 6.5% of the company.
Learn More about insider trades at Xeris Biopharma. Information on this page was last updated on 3/20/2025.
